Is it time to change the way we detect Alzheimer’s disease and monitor its progression? Towards affordable and theory-driven approaches from cognitive neurosciences

Abstract

A large proportion of people suffering from Alzheimer’s disease (AD) worldwide are not receiving a timely diagnosis. The tools currently used to detect AD and monitor its progression are not sensitive to the preclinical stages and lack specificity for correct
diagnosis. Available biomarkers show acceptable levels of sensitivity but remain littlespecific and not accessible to everyone. We embrace the view that enhancing cognitive assessment of AD should be a research priority. This Perspective paper focuses on issues which, to our view, have been preventing cognitive tests from meeting outstanding needs in the early of detection, monitoring, and treatment development of AD dementia.
We first outline the limitations of current diagnostic procedures both theoretically and practically. We then provide a rationale for theory-driven cognitive approaches which would allow mapping assessment tools to specific neuropathological stages of the neurodegenerative course of AD. Finally, we propose research strategies that would help test a hypothesis which, though launched five years ago, remains untested.
That is: “Which memory system is impaired first in Alzheimer’s disease?”
Original languageEnglish
JournalJSM Alzheimer’s Disease and Related Dementia
Volume3
Issue number2
StatePublished - 2016

Fingerprint

Neurosciences
Alzheimer Disease
diagnosis
assessment
tool
test
research
Dementia
Biological Markers
cognitive theory
neurosciences
dementia
diagnostic
priority
memory
hypothesis
procedure
need
course
perspective

Keywords

  • Alzheimer disease
  • Mild cognitive impairments
  • Cognitive neuroscience
  • Biomarkers
  • Cognitive markers

Cite this

@article{c602c6437fa44763839c3c8538592ced,
title = "Is it time to change the way we detect Alzheimer’s disease and monitor its progression? Towards affordable and theory-driven approaches from cognitive neurosciences",
keywords = "Alzheimer disease, Mild cognitive impairments, Cognitive neuroscience, Biomarkers, Cognitive markers",
author = "Serge Hoefeijzers and Clara Calia and {Parra Rodriguez}, Mario",
year = "2016",
volume = "3",
journal = "JSM Alzheimer’s Disease and Related Dementia",
issn = "2378-9565",
number = "2",

}

TY - JOUR

T1 - Is it time to change the way we detect Alzheimer’s disease and monitor its progression? Towards affordable and theory-driven approaches from cognitive neurosciences

AU - Hoefeijzers,Serge

AU - Calia,Clara

AU - Parra Rodriguez,Mario

PY - 2016

Y1 - 2016

N2 - A large proportion of people suffering from Alzheimer’s disease (AD) worldwide are not receiving a timely diagnosis. The tools currently used to detect AD and monitor its progression are not sensitive to the preclinical stages and lack specificity for correctdiagnosis. Available biomarkers show acceptable levels of sensitivity but remain littlespecific and not accessible to everyone. We embrace the view that enhancing cognitive assessment of AD should be a research priority. This Perspective paper focuses on issues which, to our view, have been preventing cognitive tests from meeting outstanding needs in the early of detection, monitoring, and treatment development of AD dementia.We first outline the limitations of current diagnostic procedures both theoretically and practically. We then provide a rationale for theory-driven cognitive approaches which would allow mapping assessment tools to specific neuropathological stages of the neurodegenerative course of AD. Finally, we propose research strategies that would help test a hypothesis which, though launched five years ago, remains untested.That is: “Which memory system is impaired first in Alzheimer’s disease?”

AB - A large proportion of people suffering from Alzheimer’s disease (AD) worldwide are not receiving a timely diagnosis. The tools currently used to detect AD and monitor its progression are not sensitive to the preclinical stages and lack specificity for correctdiagnosis. Available biomarkers show acceptable levels of sensitivity but remain littlespecific and not accessible to everyone. We embrace the view that enhancing cognitive assessment of AD should be a research priority. This Perspective paper focuses on issues which, to our view, have been preventing cognitive tests from meeting outstanding needs in the early of detection, monitoring, and treatment development of AD dementia.We first outline the limitations of current diagnostic procedures both theoretically and practically. We then provide a rationale for theory-driven cognitive approaches which would allow mapping assessment tools to specific neuropathological stages of the neurodegenerative course of AD. Finally, we propose research strategies that would help test a hypothesis which, though launched five years ago, remains untested.That is: “Which memory system is impaired first in Alzheimer’s disease?”

KW - Alzheimer disease

KW - Mild cognitive impairments

KW - Cognitive neuroscience

KW - Biomarkers

KW - Cognitive markers

M3 - Article

VL - 3

JO - JSM Alzheimer’s Disease and Related Dementia

T2 - JSM Alzheimer’s Disease and Related Dementia

JF - JSM Alzheimer’s Disease and Related Dementia

SN - 2378-9565

IS - 2

ER -